免疫抑制疗法在扩散性皮肤系统性硬化症治疗中的比较有效性
Barbara White1, Daniel E Furst2, Tracy M Frech3
1Corbus Pharmaceuticals Holdings Inc, Norwood, Massachusetts, USA (current address: SFJ Pharmaceuticals, Inc, Pleasanton, California, USA).
ACR open rheumatology
|March 11, 2025
概括
菌酸莫菲蒂尔 (MMF) 对于扩散性皮肤全身性硬化症 (dcSSc) 有效,特别是在早期阶段. 货币货币基金提供了显著的皮肤和肺部益处,特别是对于具有特定自身抗体的患者.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 扩散性皮肤全身性硬化症 (dcSSc) 是一种严重的自身免疫性疾病.
- 免疫抑制疗法 (IST) 经常用于dcSSc管理.
- 在RESOLVE-1试验提供了一个机会,以评估不同的IST在dcSSc.
研究的目的:
- 为了比较各种免疫抑制疗法 (IST) 在患有扩散性皮肤全身性硬化症 (dcSSc) 的患者的疗效.
- 评估不同IST对dcSSc.皮肤和肺部表现的影响.
- 确定可能从特定的IST中受益最多的患者子组.
主要方法:
- 分析了RESOLVE-1试验的数据,其中包括dcSSc.dc的lenabasum治疗.
- 根据使用的免疫抑制疗法 (IST) 的背景,对患者进行分类.
- 评估疗效终点,包括修改的罗丹皮肤评分 (mRSS) 和强迫生命能力 (FVC).
主要成果:
- 甲酸莫菲蒂尔 (MMF) 在皮肤得分 (mRSS) 中表现出最大的改善,特别是在早期dcSSc (持续时间≤2年) 中.
- 在52周的时间里,MMF治疗有助于稳定肺功能 (FVC),不同于没有接受IST的患者.
- 阳性抗毒素酶1抗体的患者显示,MMF对皮肤和肺部的结果有更大的益处.
结论:
- 这些发现强烈支持在dcSSc治疗中常规使用MMF.
- 对于dcSSc.早期的患者来说,MMF特别有益.
- 患有肺纤维化高危抗体的患者可能特别受益于MMF治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
190
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
190


